Biogen Message Board - Msg: 11176365

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen

BIIB 170.68

+3.2%

11:53 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: dmkst1 who wrote (1127)	9/7/1999 12:34:00 PM
From: Harold Engstrom	Read Replies (3) of 1686

jimb, 1. Probably a non-factor. That road has been travelled and paced out a few times now. 2. Actually, last year did not see flat growth during this quarter in Europe. It surprised analysts and is likely to do so again. Remember, new countries are coming on line all the time now. 3. I think this is also a non-issue. Biogen has targeted Amevive for launch in late 2001 (roughly). 4. As far as PE goes, Biogen should earn close to $2 over the next year, a significant rise over the past 12 months and a growth rate that many people thinks justifies a high PE. What acceptable PE ratios will be in the future is anyone's guess.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next